Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
 BACK TO LIST

European Patient Summary

Patient
Name: Cantón, , Urbano,
DOB: 01-APR-1945 (Age: 80)
Gender: male
ID: 8854-480268-4 (ECI)
Author
Dr. Ping, Hel
Patient summary Document
European Patient Summary
Report Date: 11-APR-2025

Problem list

Condition Onset Date Status
Hyperlipidemia 22-Mar-2022 active
Acute non-ST segment elevation myocardial infarction 15-Sep-2000 active
Dependent drug abuse 27-Oct-1991 active
Chronic intractable migraine without aura 28-Apr-1990 active
Ischemic heart disease 06-Sep-1988 active
Neuropathy due to type 2 diabetes mellitus 09-Aug-1983 active
Hyperglycemia 25-Nov-1975 active
Metabolic syndrome X 24-Jun-1975 active
Hypertriglyceridemia 18-Jun-1974 active
Type 2 diabetes mellitus 12-Jun-1973 active
Essential hypertension 12-Jun-1973 active
Anemia 12-Jun-1973 active
Chronic sinusitis 08-Feb-1965 active

Medication list

Medication Since Form Dosage Reason
Simvastatin 10 mg oral tablet 2025-04-11 - 1 tablet (10 mg) by mouth once daily Hyperlipidemia
Hydrochlorothiazide 25 mg oral tablet 2025-04-08 - 1 tablet (25 mg) by mouth once daily Essential hypertension (disorder)
Lisinopril 10 mg oral tablet 2025-04-08 - 1 tablet (10 mg) by mouth once daily Essential hypertension (disorder)
Metformin hydrochloride 500 mg prolonged-release oral tablet 2025-04-08 - 1 tablet (500 mg) once daily Diabetes mellitus type 2 (disorder)
Nitroglycerin 400 microgram/actuation sublingual spray 1988-09-13 - 400 micrograms (1 spray) sublingually as needed for chest pain, may repeat every 5 minutes as needed, up to 3 sprays in 15 minutes -
Metoprolol tartrate (as metoprolol succinate) 100 mg prolonged-release oral tablet 1988-09-13 - 1 tablet (100 mg) once daily -
Vitamin B12 5 MG/ML Injectable Solution 1973-06-19 - 1 mL (5 mg) intramuscularly once monthly -

Immunizations list

Vaccine Date
Influenza virus antigen only vaccine product 08-Apr-2025
Clostridium tetani toxoid antigen adsorbed only vaccine product 28-Mar-2023
SARS-CoV-2 mRNA vaccine 05-Oct-2021

Procedure History list

Procedure Date Reason
Depression screening 22-Sep-2020 -
Medication reconciliation 22-Sep-2020 -
Assessment of health and social care needs 22-Sep-2020 -
Depression screening using Patient Health Questionnaire Two-Item score (procedure) 22-Sep-2020 -
Assessment using Morse Fall Scale 18-Aug-2020 -
Radiography of wrist 03-Oct-2019 -
Bone immobilization 03-Oct-2019 Fracture subluxation of wrist
Bone density scan 03-Oct-2019 Fracture subluxation of wrist
Pre-discharge assessment 04-May-2017 -
Discharge from skilled nursing facility (procedure) 04-May-2017 -
Nursing care/supplementary surveillance 03-May-2017 -
Physical therapy procedure 01-May-2017 -
Speech and language therapy regime 28-Apr-2017 -
Professional / ancillary services care 28-Apr-2017 -
Occupational therapy 16-Apr-2017 -
History AND physical examination 28-Mar-2017 -
Initial patient assessment 28-Mar-2017 -
Development of individualized plan of care 28-Mar-2017 -
Screening for domestic abuse 07-Jun-2016 -

Allergies and Intolerances

Allergy/Intolerance Onset Date Status Type Reaction
? active ?

Care Plan

Active Planned Care / Goals Start Date Reason
Hyperlipidemia clinical management plan 12-Apr-2022 Hyperlipidemia
  • Achieve and maintain LDL cholesterol below 1.8 mmol/L to reduce cardiovascular risk.
  • Achieve and maintain total cholesterol below 4.0 mmol/L.
  • Achieve and maintain fasting triglycerides below 1.7 mmol/L.
  • Maintain HDL cholesterol above 1.0 mmol/L.
Care plan 14-Nov-1992 -
Lifestyle education regarding hypertension 12-Jun-1973 Essential hypertension (disorder)
  • Patient will receive education on lifestyle modifications to help control blood pressure, including diet, exercise, and medication adherence.
  • Maintain blood pressure below 130/80 mmHg
Diabetes self management plan 12-Jun-1973 Diabetes mellitus type 2 (disorder)
  • Patient will demonstrate understanding of diabetes self-management principles including medication adherence, blood glucose monitoring, diet, and physical activity.
  • Achieve and maintain target hemoglobin A1c level as recommended for older adults with comorbidities.
  • Maintain fasting blood glucose within individualized target range.
  • Maintain blood pressure within individualized target range to reduce cardiovascular risk.
  • Achieve and maintain LDL cholesterol at target level to reduce cardiovascular risk.
Immunization Recommendation Due Date Reason
Vaccine product containing only Influenza virus antigen (medicinal product) 01-Oct-2025 Annual seasonal influenza vaccination

Vital Signs

Vital Signs 2025-04-08 2024-04-02
Body Height 164.3 cm 164.3 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported 1 {score} 2 {score}
Body Weight 74.8 kg 74.8 kg
Body mass index (BMI) [Ratio] 27.7 kg/m2 27.7 kg/m2
Diastolic Blood Pressure 83 mm[Hg] 82 mm[Hg]
Systolic Blood Pressure 109 mm[Hg] 113 mm[Hg]
Heart rate 88 /min 71 /min
Respiratory rate 12 /min 14 /min

Relevant diagnostic tests/laboratory data

Recent Lab Observations 11-APR-2025 Reference Range Unit
Glucose [Mass/volume] in Blood 81.2 70 - 140 mg/dL
Urea nitrogen [Mass/volume] in Blood 10.3 7 - 25 mg/dL
Creatinine [Mass/volume] in Blood 2.6 H 0.9 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 9.0 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 138.9 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.6 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 108.3 98 - 110 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 23.2 22 - 29 mmol/L
Protein [Mass/volume] in Serum or Plasma 7.0 6 - 8.3 g/dL
Albumin [Mass/volume] in Serum or Plasma 3.8 3.2 - 5.5 g/dL
Globulin [Mass/volume] in Serum by calculation 2.2 1.5 - 3.5 g/L
Bilirubin.total [Mass/volume] in Serum or Plasma 1.1 0.3 - 1.2 mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 101.7 39 - 147 U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 42.8 7 - 60 U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29.3 10 - 40 U/L
Cholesterol [Mass/volume] in Serum or Plasma 197.6 100 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 192.1 H 45 - 175 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 134.4 0 - 190 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 59.4 40 - 100 mg/dL

Device Use

Device Date (since)
Blood glucose meter (physical object) 12-Jun-1973
Home nebulizer (physical object) 08-Feb-1965